AI assistant
NANOVEU LIMITED — Capital/Financing Update 2021
Nov 10, 2021
65457_rns_2021-11-10_7a980cc9-9d09-4a12-b999-71b5318d69e5.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Nanoveu Limited U1, 18 Olive Street Subiaco WA 6008 +61 8 6244 9095 www.nanoveu.com
==> picture [159 x 43] intentionally omitted <==
ASX RELEASE
11 November 2021 ASX: NVU
Update on Performance Rights
Nanoveu Limited (“Nanoveu” or the “Company”) is pleased to advise it has signed an exclusive agreement for the commercial and marketing rights of all antiviral products developed by Innox Limited. The agreement is for a term of 20 years. The consideration under the agreement is $1 plus 500,000 shares in the Company, being the Tranche M Performance Rights: the Company securing exclusive commercial and marketing rights of all antiviral products developed by Innox Limited, by 31 December 2021 as validated by an exclusive licencing agreement.
Accordingly, the Tranche M Performance Rights have vested with 500,000 ordinary shares being issued.
An Appendix 2A to apply to the ASX for quotation of 500,000 ordinary shares has been lodged directly on the ASX platform to update the capital structure of Nanoveu.
Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)
The Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the "Corporations Act") that:
-
the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act ;
-
as at the date of this notice the Company has complied with:
-
(a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
-
(b) section 674 of the Corporations Act ; and
as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act ) which is required to be disclosed by the Company.
- Ends -
This announcement has been authorised for release by Nanoveu’s Managing Director and CEO.
| For further information, please contact: Scott Beeton Non-executive Chairman t: +65 6557 0155 e: [email protected] |
For media / investor enquiries, please contact: Jane Morgan Investor Relations t: 0405 555 618 e: [email protected] |
|---|---|
==> picture [115 x 27] intentionally omitted <==
About Nanoveu Limited
We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. https://www.nanoveu.com/
Nanoshield - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.
EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.
Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.
EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.
2